HK1088241A1 - CCI-779 for treating mantle cell lymphoma - Google Patents

CCI-779 for treating mantle cell lymphoma

Info

Publication number
HK1088241A1
HK1088241A1 HK06108766A HK06108766A HK1088241A1 HK 1088241 A1 HK1088241 A1 HK 1088241A1 HK 06108766 A HK06108766 A HK 06108766A HK 06108766 A HK06108766 A HK 06108766A HK 1088241 A1 HK1088241 A1 HK 1088241A1
Authority
HK
Hong Kong
Prior art keywords
cci
cell lymphoma
mantle cell
treating mantle
treating
Prior art date
Application number
HK06108766A
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1088241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of HK1088241A1 publication Critical patent/HK1088241A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK06108766A 2003-11-04 2006-08-08 CCI-779 for treating mantle cell lymphoma HK1088241A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04
PCT/US2004/035900 WO2005046681A1 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma

Publications (1)

Publication Number Publication Date
HK1088241A1 true HK1088241A1 (en) 2006-11-03

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06108766A HK1088241A1 (en) 2003-11-04 2006-08-08 CCI-779 for treating mantle cell lymphoma

Country Status (31)

Country Link
US (2) US20050113403A1 (ru)
EP (1) EP1682131B9 (ru)
JP (1) JP4856548B2 (ru)
KR (1) KR101387988B1 (ru)
CN (1) CN1901906B (ru)
AR (1) AR046194A1 (ru)
AT (1) ATE373477T1 (ru)
AU (1) AU2004289213B2 (ru)
BR (1) BRPI0415714A (ru)
CA (1) CA2543665C (ru)
CO (1) CO5690605A2 (ru)
CR (1) CR8383A (ru)
DE (1) DE602004009098T2 (ru)
DK (1) DK1682131T3 (ru)
EC (1) ECSP066600A (ru)
ES (1) ES2291954T3 (ru)
GT (1) GT200400224A (ru)
HK (1) HK1088241A1 (ru)
IL (2) IL175128A0 (ru)
MY (1) MY136436A (ru)
NO (1) NO20062271L (ru)
PA (1) PA8616601A1 (ru)
PE (1) PE20051000A1 (ru)
PL (1) PL1682131T3 (ru)
PT (1) PT1682131E (ru)
RU (1) RU2358731C2 (ru)
SA (1) SA04250375B1 (ru)
TW (1) TW200517116A (ru)
UA (1) UA83697C2 (ru)
WO (1) WO2005046681A1 (ru)
ZA (1) ZA200603533B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2008066783A2 (en) * 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
ES2313983T3 (es) 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
HUP0400006A2 (hu) 2001-06-01 2004-04-28 Wyeth Antineopláziás kombinációs készítmények
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
ES2485841T3 (es) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
RU2358731C2 (ru) 2009-06-20
DE602004009098D1 (de) 2007-10-31
UA83697C2 (ru) 2008-08-11
AU2004289213A1 (en) 2005-05-26
US20050113403A1 (en) 2005-05-26
CA2543665C (en) 2009-07-14
ES2291954T3 (es) 2008-03-01
DK1682131T3 (da) 2008-01-28
EP1682131B1 (en) 2007-09-19
PE20051000A1 (es) 2006-02-03
AR046194A1 (es) 2005-11-30
KR101387988B1 (ko) 2014-04-22
EP1682131B9 (en) 2009-03-25
JP4856548B2 (ja) 2012-01-18
NO20062271L (no) 2006-07-21
GT200400224A (es) 2005-06-06
DE602004009098T2 (de) 2008-06-26
ZA200603533B (en) 2007-07-25
CR8383A (es) 2006-10-04
WO2005046681A1 (en) 2005-05-26
IL220080A0 (en) 2012-07-31
CN1901906B (zh) 2011-11-16
PA8616601A1 (es) 2006-06-02
CA2543665A1 (en) 2005-05-26
CN1901906A (zh) 2007-01-24
TW200517116A (en) 2005-06-01
SA04250375B1 (ar) 2007-08-13
KR20060111559A (ko) 2006-10-27
PT1682131E (pt) 2007-11-08
IL175128A0 (en) 2008-04-13
EP1682131A1 (en) 2006-07-26
BRPI0415714A (pt) 2006-12-19
CO5690605A2 (es) 2006-10-31
ECSP066600A (es) 2006-10-25
RU2006119451A (ru) 2007-12-20
US8507518B2 (en) 2013-08-13
JP2007510721A (ja) 2007-04-26
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
US20110184010A1 (en) 2011-07-28
ATE373477T1 (de) 2007-10-15
AU2004289213B2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
EP1660026A4 (en) TREATMENT FOR CD5 + B CELL LYMPHOMA
EP1968582A4 (en) TREATMENT OF LYMPHOMA T CUTANE
PT1479187E (pt) Controlar níveis de acesso em telefones por certificados
IL164352A0 (en) Methods for treating tweak-related conditions
EP1471902A4 (en) METHOD FOR TREATING HEARING LOSS
EP1989528A4 (en) CELL SUPPORT
IL220080A0 (en) Cci-779 for treating mantle cell lymphoma
EP1519543A4 (en) CELLULAR REMOTE SPEAKER
GB2425617B (en) Device for preventing and treating myopia
EP1705740A4 (en) FUEL FOR FUEL CELL, FUEL CELL AND USE THEREOF
GB0206357D0 (en) Cells
HK1048599A1 (zh) 癌細胞植入抑制劑
GB0120311D0 (en) Treating cells
SI1682131T1 (sl) CCI-779 za zdravljenje limfoma plascnih celic
GB2403869B (en) Radiotelephone device
GB0407620D0 (en) Cell lines
GB2422600B (en) Sludge treatment
GB0323078D0 (en) Sewage treatment
GB0013817D0 (en) Method for treating cells
GB0223325D0 (en) Treating cancer
EP1660544A4 (en) ELIMINATION OF ARSENIC
TW592216U (en) Rapid sewage treatment device
IL153749A0 (en) Improvements for diapers
GB2400846B (en) Sewage treatment
GB0325461D0 (en) Cellular reprogramming factors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111028